Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R. Obermannová
Biomarker Analysis Beyond Angiogenesis: RAS/RAF Mutation Status, Tumour Sidedness, and Second-Line Ramucirumab Efficacy in Patients With Metastatic Colorectal Carcinoma From RAISE, a Global Phase 3 Study
Annals of Oncology
Medicine
Oncology
Hematology
Related publications
Baseline Carcinoembryonic Antigen as a Predictive Factor of Ramucirumab Efficacy in RAISE, a Second-Line Metastatic Colorectal Carcinoma Phase III Trial
European Journal of Cancer
Cancer Research
Oncology
Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist
Cancer Research
Medicine
Oncology
Mutation Analysis of Key Genes in RAS/RAF and PI3K/PTEN Pathways in Chinese Patients With Hepatocellular Carcinoma
Oncology Letters
Cancer Research
Oncology
A Multi-Center Phase II Study and Biomarker Analysis of Combined Cetuximab and Modified FOLFIRI as Second-Line Treatment in Patients With Metastatic Gastric Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
Deficient Mismatch Repair and RAS Mutation in Colorectal Carcinoma Patients: A Retrospective Study in Eastern China
PeerJ
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
Neuroscience
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Impact of Primary Tumour Location on Second- Or Later-Line Treatment Outcomes in Patients With RAS Wild-Type Metastatic Colorectal Cancer and in All Lines of Treatment in Patients With RAS Mutations in Four Randomised Panitumumab Studies
Clinical Colorectal Cancer
Oncology
Gastroenterology
